Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
IntroductionSézary syndrome (SS) is an aggressive variant of cutaneous T-cell lymphoma (CTCL) that presents with generalized erythroderma, lymphadenopathy, peripheral blood involvement, and severe pruritus. Unfortunately, the disease can relapse or progress and generally has a poor prognosis. Mogamu...
Saved in:
| Main Authors: | Jordan Pilkington, Sophia Ly, Delice Kayishunge, Cesar Gentille, Henry K. Wong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1557641/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient
by: Pier Luigi Zinzani, et al.
Published: (2020-06-01) -
Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab
by: Lukas D. Uleer, et al.
Published: (2025-06-01) -
HDAC10 and its implications in Sézary syndrome pathogenesis
by: Monika Pieniawska, et al.
Published: (2025-01-01) -
Sustained Complete Remission in Sézary Syndrome using Extracorporeal Photopheresis: A Multicentric Case Series
by: Rohat Cankaya, et al.
Published: (2024-11-01) -
Current Opportunities for Treatment Optimization of Mycosis Fungoides and Sezary Syndrome
by: NG Chernova, et al.
Published: (2018-01-01)